pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 14·1 min read
save

AVB-001 Encapsulated IL-2 Cell Therapy Shows Safety and Immune Activity in Platinum-Resistant HGSOC

May 14, 2026·read at onclive ↗

AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.

read at onclive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PLATINUM2
topics
Cell TherapyImmunology

related stories

  • May 12GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive
  • May 8OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026onclive
  • May 7Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026onclive
  • May 13Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapyonclive
  • May 12Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanomaonclive